Author:
Dinh Aurélien,Davido Benjamin,Calin Ruxandra,Paquereau Julie,Duran Clara,Bouchand Frédérique,Phé Véronique,Chartier-Kastler Emmanuel,Rottman Martin,Salomon Jérôme,Plésiat Patrick,Potron Anaïs
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Cubist Pharmaceuticals Inc. Zerbaxa (ceftolozane/tazobactam) for injection, for intravenous use (package insert). 2014. Available at
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf
(accessed 19 September 2016).
2. Hong M-C, Hsu DI, Bounthavong M . Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist 2013; 6: 215–223.
3. Dinh A, Toumi A, Blanc C, Descatha A, Bouchand F, Salomon J et al. Management of febrile urinary tract infection among spinal cord injured patients. BMC Infect Dis 2016; 16: 156.
4. Farrell DJ, Flamm RK, Sader HS, Jones RN . Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother 2013; 57: 6305–6310.
5. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60: 1462–1471.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献